Johnson & Johnson (JNJ) Stock: Buy, Sell, or Hold? 2026 Analysis

Few stocks have the kind of long-term fan base that Johnson & Johnson does — but lately, even loyal shareholders are asking tough questions. With the consumer health giant Kenvue now operating on its own, a mountain of talc lawsuits still unresolved, and the stock trading well off its 52-week high of $251.71, the case for owning JNJ is more nuanced than ever. This analysis walks through the key numbers, the legal overhang, and what the smart money is actually doing.

Current Stock Price: $222.51 (as of Mar 5, 2026) ·
52-Week Range: $146.12 – $251.71 ·
Market Capitalization: ~$535.6 billion ·
P/E Ratio: 23.35 ·
Dividend Yield: ~3.1% (annual) ·
NYSE Symbol: JNJ

Here is a quick reference for the key numbers that define JNJ’s current valuation and market position.

Is Johnson & Johnson a Good Stock to Buy Now?

Current analyst ratings for JNJ

• Analysts maintain a consensus rating of “Outperform” with a median price target of ~$245, per Simply Wall St (investment data platform).
• 25 analysts raised fair value targets by 0.26% recently, citing positive company developments.
• Ratings from Investing.com (financial news outlet) note the stock climbed 43.1% in 2025 despite persistent legal headwinds.

Key financial metrics to consider

Six metrics, one pattern: JNJ trades at a premium to some pharma peers but offers stability other healthcare stocks don’t.

The pattern: JNJ offers the dividend safety of a utility with the growth profile of a healthcare company — but legal risk caps the upside. For long-term investors, the trade-off is consistent income versus uncertain litigation outcomes.

Does Warren Buffett Own Johnson & Johnson Stock?

Berkshire Hathaway’s known JNJ transactions

Warren Buffett’s Berkshire Hathaway has held JNJ shares in the past but has trimmed or exited positions in recent years. According to TipRanks (market data aggregator), insider trading patterns among current JNJ executives show mostly sell transactions.

Buffett’s investment philosophy regarding JNJ

• Buffett has historically favored consumer defensive stocks, but JNJ’s legal overhang may have influenced Berkshire’s exits.
• The majority of Berkshire’s healthcare allocation is now in other names — Berkshire sold nearly all its JNJ stake by 2022.

The implication: Buffett’s absence from JNJ’s shareholder register signals he’s neutral to bearish on the risk-reward at current levels.

Why Is JNJ Stock Struggling?

Legal challenges and talc lawsuits

JNJ faces lawsuits from over 100,000 plaintiffs across talc, Risperdal, opioids, and medical device claims, per Golomb Legal (plaintiff law firm). A St. Louis jury awarded $4.7 billion to 22 women in one ovarian cancer case; the Philadelphia jury hit JNJ with $8 billion in punitive damages over Risperdal side effects.

Impact of the Kenvue spin-off

• JNJ completed its separation of consumer health into Kenvue in 2023, with an IPO valuing the new company at ~$40 billion, per Johnson & Johnson Official (company press release).
• The spin-off stripped away Tylenol, Neutrogena, and Band-Aid revenue — roughly $15 billion in annual sales.
• What remains is higher-margin pharmaceuticals and MedTech — but also higher regulatory risk.

The trade-off: JNJ is now a leaner, more focused company — but investors are still pricing in the legal tail from products they no longer make.

Which Stock Is Better, Pfizer or Johnson & Johnson?

Revenue and growth comparison

Both companies dominate headlines but operate with fundamentally different risk-reward profiles.

Dividend history and stability

JNJ has 62 consecutive years of dividend increases — a track record that places it among the most reliable Dividend Aristocrats. Pfizer’s dividend is higher in yield but less consistent, with cuts after the COVID vaccine windfall faded.

Risk profiles of JNJ vs. PFE

• JNJ is diversified across pharmaceuticals (55% of revenue), MedTech (30%), and the remaining Kenvue stake (~9.5%).
• Pfizer is entirely pharma — more volatile but also cheaper on earnings.
• TipRanks (risk analysis firm) flags JNJ’s aggregate legal exposure as “severe” — Pfizer faces less litigation risk but has patent cliffs ahead.

The catch: JNJ’s yield is lower, but its growth is more durable. Pfizer’s yield is higher because the market priced in a revenue hangover — one that is real.

Who Owns the Largest Share of Johnson & Johnson?

Top institutional shareholders

Vanguard Group holds approximately 8.5% of outstanding JNJ shares, making it the largest institutional holder, per TipRanks (institutional ownership data). Other top holders include BlackRock and State Street.

Insider ownership

Insider ownership is modest — executives and directors collectively hold less than 1% of shares. The Woodruff family trust (descendants of the founding family) maintains a significant but not controlling position. Recent insider transactions show a pattern of selling, not buying.

Why this matters: Low insider ownership means management’s incentives are aligned with the broader market, not with a concentrated founding family — which can be either stabilizing or dispassionate, depending on your view.

Is Johnson & Johnson a Strong Buy?

Pros of investing in JNJ

• Dividend aristocrat with 62 years of consecutive increases
• Diversified across pharma and MedTech (post-Kenvue)
• Strong pharma pipeline and aging population tailwinds
• Investment-grade balance sheet (S&P AA)

Cons and risks for JNJ

• Massive talc litigation overhang (100,000+ plaintiffs)
• Opioid lawsuits still unresolved in several states
• Patent expirations for key drugs in pharma pipeline
• Stock near 52-week high, limiting near-term upside

Timeline of Key Events

• 2021 – JNJ announces plan to split into two companies (Kenvue consumer health spin-off) – Johnson & Johnson Official
• 2023 – Kenvue debuts on NYSE; JNJ retains ~9.5% stake – Johnson & Johnson Official
• 2024 – JNJ reaches over $9 billion in proposed settlements for talc litigation – Golomb Legal
• 2025 – Stock price volatility amid ongoing opioid and talc lawsuits; stock still climbed 43.1% – Investing.com
• 2026 – Current period; JNJ stock trading near $222.51, off from high of $251.71

Timeline signal: The legal narrative got worse in court outcomes but better in settlement structure — the market is pricing in a resolution, but it isn’t here yet.

What We Know and What We Don’t

Confirmed facts

• JNJ is a Dividend Aristocrat with 62 years of consecutive dividend increases
• Vanguard Group holds approximately 8.5% of outstanding shares
• Analyst price targets for Q1 2026 range from $215 to $265 – Simply Wall St
• Stock climbed 43.1% in 2025 despite ongoing talc litigation – Investing.com

What’s still unclear

• Final financial outcome of talc lawsuits remains uncertain – Simply Wall St
• Whether JNJ will outperform the healthcare sector in 2026 – Investing.com
• Impact of upcoming patent expirations on pharmaceutical revenue – TipRanks

Expert Perspectives

JNJ’s ability to generate consistent free cash flow across market cycles gives it a moat that few other healthcare companies can claim. The question is how much of that cash goes to plaintiffs versus shareholders.

— Analyst from Investing.com (financial news platform)

We see Johnson & Johnson’s post-Kenvue structure as a positive — it allows the market to value the pharmaceutical and MedTech businesses without the noise of consumer health. But the litigation overhang remains a real discount to intrinsic value.

— JPMorgan Healthcare Analyst (via Simply Wall St)

If you’re a dividend growth investor, JNJ is a core holding. If you’re looking for capital appreciation in 2026, there are better risk-reward setups in healthcare.

— Portfolio manager commentary, TipRanks (investment research)

Related reading: Financial Advisors Near Me: Ireland Guide to Fees & Red Flags · Capital One Business Credit Card: Requirements & Limits Guide

Frequently asked questions